Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in advanced gastric or gastroesophageal junction adenocarcinoma
NCT07115485Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Henlius. Started Sep 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07115485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115485.